Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Alterity Therapeutics Limited before investing.

In this article, we go over a few key elements for understanding Alterity Therapeutics Limited’s stock price such as:

• Alterity Therapeutics Limited’s current stock price and volume
• Why Alterity Therapeutics Limited’s stock price changed recently
• Upgrades and downgrades for ATHE from analysts
• ATHE’s stock price momentum as measured by its relative strength

About Alterity Therapeutics Limited (ATHE)

Before we jump into Alterity Therapeutics Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Want to learn more about Alterity Therapeutics Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Alterity Therapeutics Limited.

Alterity Therapeutics Limited’s Stock Price as of Market Close

As of December 02, 2025, 1:57 PM, CST, Alterity Therapeutics Limited’s stock price was $3.380.

Alterity Therapeutics Limited is up 3.37% from its previous closing price of $3.270.

During the last market session, Alterity Therapeutics Limited’s stock traded between $3.250 and $3.440. Currently, there are approximately 4,904.23 million shares outstanding for Alterity Therapeutics Limited.

Alterity Therapeutics Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Alterity Therapeutics Limited Stock Price History

Alterity Therapeutics Limited’s (ATHE) price is currently down 6.1% so far this month.

During the month of December, Alterity Therapeutics Limited’s stock price has reached a high of $3.580 and a low of $3.250.

Over the last year, Alterity Therapeutics Limited has hit prices as high as $7.000 and as low as $1.410. Year to date, Alterity Therapeutics Limited’s stock is up 2.12%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Alterity Therapeutics Limited Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there were analysts who downgraded Alterity Therapeutics Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Alterity Therapeutics Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Alterity Therapeutics Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Alterity Therapeutics Limited (ATHE) by visiting AAII Stock Evaluator.

Relative Price Strength of Alterity Therapeutics Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, Alterity Therapeutics Limited has a weighted four-quarter relative price strength of 43.25%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Alterity Therapeutics Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Alterity Therapeutics Limited Stock Price: Bottom Line

As of December 2, 2025, Alterity Therapeutics Limited’s stock price is $3.380, which is up 3.37% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Alterity Therapeutics Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.